Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality

[1]  F. Pourfarzi,et al.  The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study , 2020, Mediterranean journal of rheumatology.

[2]  Bruno Luís de Castro Araujo.  Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2021, Annals of Internal Medicine.

[3]  J. Ge,et al.  A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of α-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Medicine.

[4]  G. Guyatt,et al.  Patient-important outcomes reported in clinical studies of pharmacologic treatments for covid-19: A protocol of a meta-epidemiological study , 2020 .

[5]  Jan A. Roth,et al.  The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days , 2020, F1000Research.

[6]  Reza Hajizadeh,et al.  The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial , 2020, BMC Infectious Diseases.

[7]  Inge Christoffer Olsen,et al.  A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics , 2020, Nature Communications.

[8]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[9]  J. Nielsen,et al.  Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19 , 2020, medRxiv.

[10]  Jan A. Roth,et al.  The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. , 2020, F1000Research.

[11]  Jennifer L. Bell,et al.  Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2020, The Lancet.

[12]  B. Abella,et al.  Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers , 2020, JAMA internal medicine.

[13]  Ke Wang,et al.  Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size , 2020, Biomedicine & Pharmacotherapy.

[14]  M. El-Sayed,et al.  A Randomized Controlled Study Of Favipiravir Vs Hydroxychloroquine In COVID-19 Management: What Have We Learned So Far? , 2020 .

[15]  P. van Paassen,et al.  Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial , 2020, The Lancet Rheumatology.

[16]  Jonathan S. Austrian,et al.  Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients , 2020, Open forum infectious diseases.

[17]  J. Marchini,et al.  Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Lahiri,et al.  Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19 , 2020, medRxiv.

[19]  Felipe García,et al.  Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial , 2020 .

[20]  S. Tajima,et al.  A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.

[21]  Dong Zhao,et al.  Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Pazin-Filho,et al.  Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) , 2020, Thrombosis Research.

[23]  J. Balko,et al.  Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial , 2020, medRxiv.

[24]  J. Myburgh,et al.  An evaluation of the quality and impact of the global research response to the COVID‐19 pandemic , 2020, The Medical journal of Australia.

[25]  A. Pizarro,et al.  Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial , 2020, medRxiv.

[26]  S. Najafizadeh,et al.  Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial , 2020, European Respiratory Journal.

[27]  H. Keyvani,et al.  Effect of Arbidol on COVID-19: A Randomized Controlled Trial , 2020 .

[28]  Y. Perera,et al.  Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial , 2020, medRxiv.

[29]  Naweed I Chowdhury,et al.  Interim analysis of an open‐label randomized controlled trial evaluating nasal irrigations in non‐hospitalized patients with coronavirus disease 2019 , 2020, International forum of allergy & rhinology.

[30]  M. Martinez-Fierro,et al.  Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial. , 2020, Research square.

[31]  W. Guan,et al.  Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[32]  Shashank Srivastava,et al.  Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) , 2020, medRxiv.

[33]  M. Zhang,et al.  Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial , 2020, Engineering.

[34]  Á. Avezum,et al.  Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial , 2020, The Lancet.

[35]  G. Guyatt,et al.  A living WHO guideline on drugs for covid-19 , 2020, BMJ.

[36]  Wenwu Zhang,et al.  Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study , 2020, Clinical and translational science.

[37]  Á. Avezum,et al.  Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. , 2020, JAMA.

[38]  D. Annane,et al.  Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[39]  Christopher M. Horvat,et al.  Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. , 2020, JAMA.

[40]  I. Douglas,et al.  Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia , 2020, medRxiv.

[41]  J. Alcamí,et al.  Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial , 2020, medRxiv.

[42]  R. Bouillon,et al.  “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study” , 2020, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  X. Yao,et al.  Tocilizumab Ameliorates the Hypoxia in COVID-19 Moderate Patients with Bilateral Pulmonary Lesions: A Randomized, Controlled, Open-Label, Multicenter Trial , 2020 .

[44]  M. Yekaninejad,et al.  Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial , 2020, International Immunopharmacology.

[45]  N. Manafi,et al.  Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial , 2020, International Journal of Antimicrobial Agents.

[46]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[47]  T. Tagaev,et al.  Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients , 2020 .

[48]  A. Davarpanah,et al.  Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial , 2020, The Journal of antimicrobial chemotherapy.

[49]  S. Merat,et al.  Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial , 2020, The Journal of antimicrobial chemotherapy.

[50]  S. Abd-Elsalam,et al.  Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study , 2020, The American journal of tropical medicine and hygiene.

[51]  L. Velloso,et al.  Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study , 2020, medRxiv.

[52]  Q. Bassat,et al.  Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  F. Pelorosso,et al.  Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report. , 2020, medRxiv.

[54]  F. Cunha,et al.  Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial , 2020, medRxiv.

[55]  Z. Meng,et al.  High-dose vitamin C infusion for the treatment of critically ill COVID-19 , 2020 .

[56]  N. Savchuk,et al.  AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  P. Niu,et al.  SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial , 2020, International Journal of Infectious Diseases.

[58]  Géric Maura,et al.  TITLE PAGE Title: Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. Authors: *Idelsis Esquivel-Moynelo I , 2020 .

[59]  G. Guyatt,et al.  Drug treatments for covid-19: living systematic review and network meta-analysis , 2020, BMJ.

[60]  F. Shan,et al.  A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19 , 2020, EClinicalMedicine.

[61]  C. Tebé,et al.  A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease , 2020, medRxiv.

[62]  R. Kullar,et al.  Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial , 2020, medRxiv.

[63]  Á. Avezum,et al.  Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 , 2020, The New England journal of medicine.

[64]  S. Safiri,et al.  Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial , 2020, BioImpacts : BI.

[65]  S. Lofgren,et al.  Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2020, Annals of Internal Medicine.

[66]  K. Stauderman,et al.  Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial , 2020, Critical Care.

[67]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.

[68]  Z. Ren,et al.  A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study , 2020, Advanced science.

[69]  Yaokai Chen,et al.  No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, , 2020, Frontiers in Pharmacology.

[70]  M. Yekaninejad,et al.  A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.

[71]  C. Hsiao,et al.  A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19) , 2020, medRxiv.

[72]  R. Dal-Ré,et al.  Waste in COVID-19 clinical trials conducted in western Europe , 2020, European Journal of Internal Medicine.

[73]  Honglin Li,et al.  A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial , 2020, Virologica Sinica.

[74]  D. Hsiehchen,et al.  Deficiencies in the Designs and Interventions of COVID-19 Clinical Trials , 2020, Med.

[75]  M. M. van der Eerden,et al.  Convalescent Plasma for COVID-19. A randomized clinical trial , 2020, medRxiv.

[76]  S. Hosseinimehr,et al.  Febuxostat therapy in outpatients with suspected COVID‐19: A clinical trial , 2020, International journal of clinical practice.

[77]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[78]  Xiang Chen,et al.  Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study , 2020, medRxiv.

[79]  J. Riancho,et al.  GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia , 2020, medRxiv.

[80]  Zheng-Yang Shi,et al.  Recombinant Super-Compound Interferon (rSIFN-co) Versus Interferon Alfa in the Treatment of Moderate-to-Severe COVID-19: A Multicentre, Randomised, Phase 2 Trial , 2020 .

[81]  H. Keskin,et al.  The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study. , 2020, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique.

[82]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[83]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[84]  G. Dangas,et al.  Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 , 2020, JAMA network open.

[85]  J. Segal,et al.  Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis , 2020, BMJ Open.

[86]  R. Bruno,et al.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[87]  Jing Liu,et al.  Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial , 2020, Journal of Allergy and Clinical Immunology.

[88]  B. Ibáñez,et al.  Ramipril in High-Risk Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[89]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[90]  J. Qu,et al.  Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.

[91]  T. Hoffmann,et al.  Waste in covid-19 research , 2020, BMJ.

[92]  T. Liang,et al.  Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial , 2020, European Journal of Pharmaceutical Sciences.

[93]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[94]  Changming Niu,et al.  Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells , 2020, Stem Cell Research & Therapy.

[95]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[96]  W. Alhazzani,et al.  COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine , 2020, Journal of Clinical Epidemiology.

[97]  Lichuan Zhang,et al.  Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment , 2020, medRxiv.

[98]  Q. Bassat,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[99]  J. Marshall,et al.  Misinformation During the Coronavirus Disease 2019 Outbreak: How Knowledge Emerges From Noise , 2020, Critical care explorations.

[100]  Duanqing Pei,et al.  Treating COVID-19 with Chloroquine , 2020, Journal of molecular cell biology.

[101]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[102]  Xilong Deng,et al.  An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) , 2020, medRxiv.

[103]  Bo Chen,et al.  Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial , 2020, medRxiv.

[104]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[105]  Shigui Yang,et al.  Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19) , 2020, Journal of Translational Medicine.

[106]  Nobuhiro,et al.  A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19 , 2020 .

[107]  B. Abella,et al.  Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial , 2020 .

[108]  J. Ioannidis,et al.  Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview , 2018, Intensive Care Medicine.

[109]  Byron C. Wallace,et al.  Machine learning for identifying Randomized Controlled Trials: An evaluation and practitioner's guide , 2018, Research synthesis methods.

[110]  A. F. Delgado,et al.  The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis. , 2017 .

[111]  Anna Falk Delgado,et al.  The association of funding source on effect size in randomized controlled trials: 2013–2015 – a cross-sectional survey and meta-analysis , 2017, Trials.

[112]  B. Vandermeer,et al.  A meta-epidemiological study to examine the association between bias and treatment effects in neonatal trials. , 2014, Evidence-based child health : a Cochrane review journal.

[113]  P. Funch‐jensen,et al.  Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain , 2013, Scandinavian journal of gastroenterology.

[114]  Zhongheng Zhang,et al.  Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study , 2013, Critical Care.

[115]  Ross J. Harris,et al.  Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. , 2012, Health technology assessment.

[116]  Karina D. Torralba,et al.  Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[117]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[118]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[119]  Zoran Bursac,et al.  Purposeful selection of variables in logistic regression , 2008, Source Code for Biology and Medicine.

[120]  Douglas G Altman,et al.  Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.

[121]  T. Carmody,et al.  An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. , 2004, Controlled clinical trials.

[122]  D. Cook,et al.  Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.

[123]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.